ClinicalTrials.gov
ClinicalTrials.gov Menu

18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01806675
Recruitment Status : Active, not recruiting
First Posted : March 7, 2013
Last Update Posted : June 5, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sanjiv Sam Gambhir, Stanford University

March 5, 2013
March 7, 2013
June 5, 2018
March 2013
December 7, 2016   (Final data collection date for primary outcome measure)
Change in maximum standard uptake values (SUVmax) on 18F FPPRGD2 and 18F FDG PET [ Time Frame: From baseline up to 6 weeks ]
Response to treatment is based on the change in PET uptake, change in CT tumor size, PET European Organization for Research and Treatment of Cancer (EORTC) response criteria, and CT Response Evaluation Criteria In Solid Tumors (RECIST) response criteria. Each of the four response criteria will be dichotomized into responding or non-responding to treatment. The Mann-Whitney test and logistic regression of response/non-response will be performed.
Same as current
Complete list of historical versions of study NCT01806675 on ClinicalTrials.gov Archive Site
Progression-free survival [ Time Frame: Up to 1 year ]
For each SUV measure patients will be divided into two groups based on whether their SUV uptake is above or below the median. Kaplan-Meir curves for the two groups will be plotted and a log-rank test for difference in PFS will be performed. A Cox proportional-hazards regression of PFS on group will be performed.
Same as current
Not Provided
Not Provided
 
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.

PRIMARY OBJECTIVES:

I. Evaluate 18F FPPRGD2 PET/CT or PET/MRI for prediction and early assessment of response to anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC), breast cancer, glioblastoma multiforme (GBM) and other cancers.

OUTLINE:

Patients undergo 18F FPPRGD2 PET/CT or PET/MRI at baseline, 1 week, and 6 weeks (or standard of care follow-up) and 18F FDG PET/CT at baseline and 6 weeks (or standard of care follow-up) .

After completion of study imaging, patients are followed up at 12 months.

Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Male Breast Cancer
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
  • Recurrent Adult Brain Tumor
  • Recurrent Basal Cell Carcinoma of the Lip
  • Recurrent Breast Cancer
  • Recurrent Colon Cancer
  • Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Hypopharyngeal Cancer
  • Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Laryngeal Cancer
  • Recurrent Lip and Oral Cavity Cancer
  • Recurrent Lymphoepithelioma of the Nasopharynx
  • Recurrent Lymphoepithelioma of the Oropharynx
  • Recurrent Metastatic Squamous Neck Cancer With Occult Primary
  • Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
  • Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
  • Recurrent Nasopharyngeal Cancer
  • Recurrent Non-small Cell Lung Cancer
  • Recurrent Oropharyngeal Cancer
  • Recurrent Pancreatic Cancer
  • Recurrent Paranasal Sinus and Nasal Cavity Cancer
  • Recurrent Rectal Cancer
  • Recurrent Renal Cell Cancer
  • Recurrent Salivary Gland Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIA Non-small Cell Lung Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIB Non-small Cell Lung Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Stage IV Non-small Cell Lung Cancer
  • Stage IV Pancreatic Cancer
  • Stage IV Renal Cell Cancer
  • Stage IVA Colon Cancer
  • Stage IVA Rectal Cancer
  • Stage IVA Salivary Gland Cancer
  • Stage IVB Colon Cancer
  • Stage IVB Salivary Gland Cancer
  • Stage IVC Salivary Gland Cancer
  • Tongue Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: fludeoxyglucose F 18
    Undergo 18F FDG PET/CT
    Other Names:
    • 18FDG
    • FDG
  • Drug: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide
    Undergo 18F FPPRGD2 PET/CT or PET/MRI
    Other Names:
    • 104150
    • 18F-FPPRGD2
    • [18F] FPPRGD2
    • fluorine 18 ((18)F) FPPRGD2
    • PEG3-E[c(RGDyk)]2
  • Diagnostic Test: positron emission tomography
    Undergo 18F FPPRGD2 PET/CT or PET/MRI
    Other Names:
    • FDG-PET
    • PET
    • PET scan
    • tomography, emission computed
    • magnetic resonance imaging
  • Diagnostic Test: computed tomography
    Undergo 18F FPPRGD2 PET/CT or PET/MRI
    Other Names:
    • tomography, computed
    • magnetic resonance imaging
  • Diagnostic Test: positron emission tomography
    Undergo 18F FDG PET/CT
    Other Names:
    • FDG-PET
    • PET
    • PET scan
    • tomography, emission computed
  • Diagnostic Test: computed tomography
    Undergo 18F FDG PET/CT
    Other Name: tomography, computed
  • Other: laboratory biomarker analysis
    Correlative studies
Experimental: Diagnostic (18F FPPRGD2 PET/CT or PET/MRI)
Patients undergo 18F FPPRGD2 PET/CT or PET/MRI imaging at baseline, 1 week, and 6 weeks (or standard of care follow-up) and 18F FDG PET/CT at baseline and 6 weeks (or standard of care follow-up) .
Interventions:
  • Drug: fludeoxyglucose F 18
  • Drug: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide
  • Diagnostic Test: positron emission tomography
  • Diagnostic Test: computed tomography
  • Diagnostic Test: positron emission tomography
  • Diagnostic Test: computed tomography
  • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
25
100
March 2019
December 7, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provides written informed consent
  • Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment
  • Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

  • Pregnant or nursing
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01806675
VARIMG0002
NCI-2013-00535 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Not Provided
Not Provided
Not Provided
Sanjiv Sam Gambhir, Stanford University
Sanjiv Sam Gambhir
National Cancer Institute (NCI)
Principal Investigator: Sanjiv Gambhir Stanford University
Stanford University
June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP